Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Bolt Biotherapeutics, Inc.

Get SEC filing alerts via email and in your feed for Bolt Biotherapeutics, Inc.

BOLT

Bolt Biotherapeutics, Inc.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for cancer treatment. Its proprietary Boltbody ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate the innate immune system against tumors. Key programs target tumor-associated macrophages and tumor antigens like claudin 18.2 and PD-L1. The company focuses on solid tumors, leveraging collaborations and third-party manufacturing to advance its pipeline globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Bolt Biotherapeutics, Inc.

1
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports Decrease in Revenue and Operating Losses for Q1 2026

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports $33.4 Million Net Loss for Fiscal Year 2025, Improved from Previous Year

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports Improved Q3 Loss of $7.1 Million, Announces New Restructuring Plan

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports $8.6 Million Net Loss in Q2 2025, Down from $21.2 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports Q1 2025 Financial Results, Revenue Declines to $1.2 Million

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports $63.1 Million Net Loss for 2024, Workforce Reduction and Restructuring Charges Noted

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Bolt Biotherapeutics, Inc. Bolt Biotherapeutics Reports Q3 2024 Financial Results, Net Loss Improves Amid Restructuring Efforts

Via official filing (AI summary) | over 1 year ago | 0 comments